Pfizer
Trade Pfizer 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About PFE
Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.
PFE Key Statistics
Stock Snapshot
As of today, Pfizer(PFE) shares are valued at $25.80. The company's market cap stands at 147.13B, with a P/E ratio of 14.87 and a dividend yield of 6.7%.
On 2025-11-13, Pfizer(PFE) stock moved within a range of $25.22 to $25.95. With shares now at $25.80, the stock is trading +2.3% above its intraday low and -0.6% below the session's peak.
Trading activity shows a volume of 96.01M, compared to an average daily volume of 133.1M.
Over the past 52 weeks, Pfizer(PFE) stock has traded between a high of $27.69 and a low of $20.92.
Over the past 52 weeks, Pfizer(PFE) stock has traded between a high of $27.69 and a low of $20.92.
PFE News
Scotiabank initiated coverage of Pfizer (PFE) with an Outperform rating and $30 price target Meet Your ETF AI Analyst Discover how TipRanks' ETF AI Analyst ca...
The biotech start-up's stock had been rising rapidly in 2025. Innovative biopharmaceutical company Metsera (MTSR 0.10%) has been climbing all year. It went pub...
Pfizer is working to deal with typical business issues in the drug space, but its attempt at a solution has become very complicated. The next three years have...
Analyst ratings
58%
of 26 ratingsMore PFE News
Analyst Terence Flynn of Morgan Stanley maintained a Hold rating on Pfizer, retaining the price target of $32.00. Meet Your ETF AI Analyst Discover how TipRanks...
Key Points Pfizer's sales and profits came in better than expected for the third quarter. The stock, however, remains down for the year. Concerns about the c...
The U.S. Department of Health and Human Services announced that the U.S. Food and Drug Administration is initiating the removal of broad “black box” warnings fr...
Metsera (MTSR) stock toppled Monday after the buyout battle with Pfizer (PFE) and Novo Nordisk (NVO) ended. Pfizer will acquire the small obesity-focused biotec...
Pfizer Inc. Chief Executive Albert Bourla had long searched for an obesity drug to make up for dwindling sales of the pharma company’s aging blockbusters. Late...
Danish drug giant Novo Nordisk’s shares rose modestly during early trading on Monday. This came after reports that Novo Nordisk’s pursuit of obesity market deal...
J.P. Morgan analyst Chris Schott has maintained their neutral stance on PFE stock, giving a Hold rating on November 6. Meet Your ETF AI Analyst Discover how Tip...